Alexandria Pharmaceuticals results, Fiscal year 2026
Net profit, assets, equity and cash flow for Fiscal year 2026, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit660 millionEGP · +1131.7% vs the same period a year earlier
Total assets1.78 billionEGP
Shareholders' equity1.18 billionEGP · +18.6% vs the same period a year earlier
Operating cash flow522 millionEGP
In short
- Alexandria Pharmaceuticals's net profit for Fiscal year 2026 was about 660 million EGP, up +1131.7% from 53.59 million EGP in Fiscal year 2025.
- Total assets at the end of Fiscal year 2026 were about 1.78 billion EGP, and shareholders' equity about 1.18 billion EGP.
- Operating cash flow for Fiscal year 2026 was positive at 522 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2025Change
Net profit660 million53.59 million+1131.7%
Gross profit1.35 billion98.72 million+1271.6%
Total assets1.78 billion——
Total liabilities597 million——
Shareholders' equity1.18 billion994 million+18.6%
Total liabilities and equity1.78 billion1.53 billion+16.3%
Operating cash flow522 million——
Investing cash flow-67.15 million——
Financing cash flow-343 million——
Net change in cash111 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy